CHMP Recommends Pfizer's Paxlovid For Use In Adults With COVID-19

The European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending the conditional approval of Pfizer Inc's PFE Paxlovid.

  • Paxlovid (nirmatrelvir and ritonavir tablets) is indicated for COVID-19 in adults who do not require supplemental oxygen and are at increased risk of progressing to severe COVID-19.
  • The CHMP based its positive opinion on the scientific evidence supporting PAXLOVID, including data from the Phase 2/3 EPIC-HR.
  • The data showed that Paxlovid reduced the risk of hospitalization or death by 89% (within three days of symptom onset) and 88% (within five days of symptom onset) compared to placebo, with no deaths observed in the treatment group. 
  • Related: Pfizer's COVID-19 Oral Antiviral Shows In-Vitro Efficacy Against Omicron Variant.
  • Paxlovid is approved or authorized for emergency use in more than ten countries.
  • Pfizer has raised its production projections, with the potential ability to produce up to 120 million courses of treatment by the end of 2022.
  • PAXLOVID is administered at a dose of 300 mg (two 150 mg tablets) of nirmatrelvir with one 100 mg tablet of ritonavir, given twice daily for five days. 
  • Price Action: PFE shares are up 2.18% at $54.17 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!